ATXS - Astria to start phase 1b/2 trial of preventative therapy for hereditary angioedema attacks
- Astria Therapeutics ( NASDAQ: ATXS ) said it started a phase 1b/2 trial of STAR-0215 as a preventative therapy for patients with hereditary angioedema (HAE).
- HAE is a disorder characterized by recurrent episodes (attacks) of severe swelling of the skin and mucous membranes.
- The company expects initial proof-of-concept data from single and multiple dose groups of the study, dubbed ALPHA-STAR, in mid-2024.
- "Our vision for STAR-0215 is to develop a long-acting, safe, and effective preventative therapy that normalizes the lives of people living with HAE," said Astria Chief Medical Officer Chris Morabito.
- ATXS +0.19% to $15.55 premarket Feb. 8
For further details see:
Astria to start phase 1b/2 trial of preventative therapy for hereditary angioedema attacks